Skye Bioscience TCAC FCF 5A

Que fait Skye Bioscience ? Skye Bioscience Inc is a biotechnology company headquartered in San Diego, California, with a focus on developing cannabinoid derivatives for therapeutic applications. The company has 11 full-time employees and went public via an IPO on February 24, 2014. Skye Bioscience operates within the health care sector, specifically in the biotechnology industry. Its primary research involves the discovery and development of cannabinoid-based compounds targeting the endocannabinoid system. The company's lead product candidate, SBI-100 OE, is under development for treating glaucoma and ocular hypertension. A first-in-human Phase I clinical trial for SBI-100 OE is currently being conducted in Australia with healthy volunteers to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Additionally, Skye Bioscience is working on SBI-200, which has shown potential in early studies for analgesic, anti-inflammatory, anti-fibrotic, and anti-seizure applications. The company also explores SBI-200's potential for treating various eye conditions, including uveitis, dry eye syndrome, macular degeneration, and diabetic-related eye diseases. Skye Bioscience maintains a website at skyebioscience.com for further information. The company's operations and product development are centered around addressing unmet medical needs through cannabinoid-based therapies. Skye Bioscience est l'une des entreprises les plus populaires sur Eulerpool.